OBJECTIVE: Function, patient global assessment, and pain are routinely measured in rheumatoid arthritis (RA) clinical trials. However, other patient-reported outcomes identified as important to patients in qualitative studies, such as fatigue and quality of life, are commonly not included, and modern treatment regimens may have changed patients' expectations of treatment outcomes. Our objective was to elicit patient priority treatment outcomes for pharmacologic interventions since the common use of anti-tumor necrosis factor (anti-TNF) therapy, which will form the basis of a core set of patient priorities to complement existing professional core sets. METHODS: In-depth interviews were conducted with 23 RA patients, purposively sampled for age, sex, medication (anti-TNF or other disease-modifying antirheumatic drugs), disease severity, and work status. Grounded theory guided iterative data collection and analysis. Coding of the data was peer reviewed. A patient research partner collaborated in the research design and analysis. RESULTS: Sixty-three different outcomes important to patients were generated from the interviews. Four major categories of patient outcomes from pharmacologic treatments were developed: "RA under control," "Doing things," "Emotional health," and "Coping with illness." The core category (or overall theme) was "Minimizing the personal impact of RA." CONCLUSION: Although the routine outcomes of pain, function, and overall well-being were raised by the patients, they also generated a further 60 important outcomes that they look for from treatment. This difference in perspective may potentially influence treatment decisions. The next step is therefore to use these data to develop a patient core set.
OBJECTIVE: Function, patient global assessment, and pain are routinely measured in rheumatoid arthritis (RA) clinical trials. However, other patient-reported outcomes identified as important to patients in qualitative studies, such as fatigue and quality of life, are commonly not included, and modern treatment regimens may have changed patients' expectations of treatment outcomes. Our objective was to elicit patient priority treatment outcomes for pharmacologic interventions since the common use of anti-tumornecrosis factor (anti-TNF) therapy, which will form the basis of a core set of patient priorities to complement existing professional core sets. METHODS: In-depth interviews were conducted with 23 RApatients, purposively sampled for age, sex, medication (anti-TNF or other disease-modifying antirheumatic drugs), disease severity, and work status. Grounded theory guided iterative data collection and analysis. Coding of the data was peer reviewed. A patient research partner collaborated in the research design and analysis. RESULTS: Sixty-three different outcomes important to patients were generated from the interviews. Four major categories of patient outcomes from pharmacologic treatments were developed: "RA under control," "Doing things," "Emotional health," and "Coping with illness." The core category (or overall theme) was "Minimizing the personal impact of RA." CONCLUSION: Although the routine outcomes of pain, function, and overall well-being were raised by the patients, they also generated a further 60 important outcomes that they look for from treatment. This difference in perspective may potentially influence treatment decisions. The next step is therefore to use these data to develop a patient core set.
Authors: Alison Carr; Sarah Hewlett; Rod Hughes; Helene Mitchell; Sarah Ryan; Maggie Carr; John Kirwan Journal: J Rheumatol Date: 2003-04 Impact factor: 4.666
Authors: C K Kwoh; G T O'Connor; M G Regan-Smith; E M Olmstead; L A Brown; J B Burnett; R F Hochman; K King; G J Morgan Journal: J Rheumatol Date: 1992-07 Impact factor: 4.666
Authors: John P A Ioannidis; Fotini B Karassa; Eric Druyts; Kristian Thorlund; Edward J Mills Journal: Nat Rev Rheumatol Date: 2013-09-03 Impact factor: 20.543
Authors: Pratik P Pandharipande; E Wesley Ely; Rakesh C Arora; Michele C Balas; Malaz A Boustani; Gabriel Heras La Calle; Colm Cunningham; John W Devlin; Julius Elefante; Jin H Han; Alasdair M MacLullich; José R Maldonado; Alessandro Morandi; Dale M Needham; Valerie J Page; Louise Rose; Jorge I F Salluh; Tarek Sharshar; Yahya Shehabi; Yoanna Skrobik; Arjen J C Slooter; Heidi A B Smith Journal: Intensive Care Med Date: 2017-06-13 Impact factor: 17.440
Authors: Alessandro Chiarotto; Richard A Deyo; Caroline B Terwee; Maarten Boers; Rachelle Buchbinder; Terry P Corbin; Leonardo O P Costa; Nadine E Foster; Margreth Grotle; Bart W Koes; Francisco M Kovacs; Chung-Wei Christine Lin; Chris G Maher; Adam M Pearson; Wilco C Peul; Mark L Schoene; Dennis C Turk; Maurits W van Tulder; Raymond W Ostelo Journal: Eur Spine J Date: 2015-04-05 Impact factor: 3.134
Authors: Paula R Williamson; Douglas G Altman; Heather Bagley; Karen L Barnes; Jane M Blazeby; Sara T Brookes; Mike Clarke; Elizabeth Gargon; Sarah Gorst; Nicola Harman; Jamie J Kirkham; Angus McNair; Cecilia A C Prinsen; Jochen Schmitt; Caroline B Terwee; Bridget Young Journal: Trials Date: 2017-06-20 Impact factor: 2.279
Authors: Elizabeth Hulen; Ayla Ervin; Allison Schue; Gina Evans-Young; Somnath Saha; Edward H Yelin; Jennifer L Barton Journal: Musculoskeletal Care Date: 2016-12-14
Authors: Adrian Mendez; Hadi Seikaly; Dean Eurich; Agnieszka Dzioba; Daniel Aalto; Martin Osswald; Jeffrey R Harris; Daniel A O'Connell; Cathy Lazarus; Mark Urken; Ilya Likhterov; Raymond L Chai; Erika Rauscher; Daniel Buchbinder; Devin Okay; Risto-Pekka Happonen; Ilpo Kinnunen; Heikki Irjala; Tero Soukka; Juhani Laine Journal: JAMA Otolaryngol Head Neck Surg Date: 2020-05-01 Impact factor: 6.223
Authors: Darija Hofmann; Fowzia Ibrahim; Diana Rose; David L Scott; Andrew Cope; Til Wykes; Heidi Lempp Journal: Health Expect Date: 2013-04-25 Impact factor: 3.377